CIK 0001690585
- Non-accelerated filer
- Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- 4 Conversion Director acquired 24,527 shares (conversion)
- 4 Conversion Director acquired 593,611 shares (conversion)
- 4 Conversion Chief Scientific Officer acquired 4,370 shares (conversion)
- 4 Conversion See Remarks acquired 4,643 shares (conversion)
- 4 Conversion Chief Business Officer acquired 2,912 shares (conversion)
- 4 Conversion 10% owner acquired 3,339,137 shares (conversion)
- 4 Conversion Director acquired 4,746,876 shares (conversion)
- 4 Conversion Director acquired 21,847 shares (conversion)
- 4 Conversion Director acquired 4,152 shares (conversion)
- 4 Conversion Director acquired 3,339,137 shares (conversion)
- 4 Conversion Chief Medical Officer acquired 8,304 shares (conversion)
- 4 Open-market buy See Remarks bought 400 shares at $15.00 ($6,000)
- 4 Conversion Director acquired 0 shares (conversion)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 14 of 15 · 290 filings